NCT03366480已完成1 期
A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 103
- 试验地点
- 1
- 主要终点
- Emergent Adverse Events
研究概览
简要总结
A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.
详细描述
This is a phase I/II multicenter divided in two phases.
Phase I: Safety and dose escalation
This study is not randomized, and all included patients will receive ABTL0812 in addition to paclitaxel + carboplatin (SOC). In this phase, patients can be selected from both indications, regardless of the number of each indication.
This phase will be divided in 2 periods:
Period 1:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients ≥18 years of age
- •Willing and able to provide informed consent
- •For endometrial cancer: Patients with advanced, metastatic or recurrent endometrial cancer, from all histological types except carcinosarcoma and leiomyosarcoma.
- •For squamous NSCLC: Patients with histologically or radiological/cytologically confirmed diagnosis (non-irradiance IIIb stage or stage IV), excluding mixed tumors, neuroendocrine or adenocarcinoma.
- •Have adequate tumor tissue available (either archival not older than 6 months or new tumor biopsy) for biomarker analyses. The most recently collected tumor tissue sample should be provided, if available.
- •Life expectancy ≥ 12 weeks in the opinion of the investigator
- •Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 guidelines with at least one "target lesion" to be used to assess response. Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- •Contraception: All female patients will be considered to be of childbearing potential unless they are postmenopausal (at least 12 months' consecutive amenorrhea, in the appropriate age group and without other known or suspected cause), or have been sterilized surgically. Female patients of childbearing potential must agree to use two forms of highly effective contraception methods during the study and for a period of 6 months following the last administration of the study drug. Male patients and their female partners, who are of childbearing potential and are not practicing total abstinence, must agree to use two forms of highly effective contraception during the study and for a period of 6 months following the last administration of the study drug.
- •Adequate bone marrow function defined as:
- •absolute neutrophil count ≥ 1.5x109/L
- •platelet count ≥ 100x109/L
- •hemoglobin ≥ 10.0 g/dL
- •Total bilirubin ≤ 1.5 x upper limit of normal
- •Aspartate transaminase (AST) ≤ 2.5 times upper limit of normal (ULN) (≤5 times the ULN in patients with evidence of liver metastases)
- •Alkaline phosphatase ≤ 2.5 times ULN (≤5 times the ULN in patients with evidence of liver metastases)
- •Glomerular filtration rate ≥ 50 mL/min
- •Serum creatinine ≤1.5 ULN
- •Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) must be resolved to ≤ grade 1 (as defined by Common Terminology Criteria for Adverse Events version 4.02).
- •Ability and willingness to comply with study visits, treatment, testing, and to comply with the protocol
排除标准
- •Patients previously treated with an inhibitor of the Phosphoinositide 3-kinase/Protein kinase B/mechanistic target of rapamycin (PI3K/Akt/mTOR) pathway.
- •Patients previously treated with adjuvant or co-adjuvant chemotherapy administered 6 months or less in advance of patient inclusion
- •Patients with symptomatic brain metastases. Patients with asymptomatic and treated brain metastases can be included in the study if they are kept on stable doses of steroids for a period of 1 month prior to study entry provided they don't have peripheric neuropathy grade 2 or superior.
- •Patients with gastrointestinal abnormalities including inability to take oral medications, malabsorption syndromes or other clinically significant gastrointestinal abnormalities that may impair the absorption of the investigational medicinal product.
- •Pregnancy or lactation. Serum pregnancy test to be performed within 7 days prior to study treatment start.
- •Patients with myocardial infarction within ≤ 12 months prior to study entry, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina pectoris, or unstable cardiac arrhythmia requiring medication.
- •Evidence of pre-existing uncontrolled hypertension. Patients whose hypertension is controlled by antihypertensive therapies are eligible.
- •Patients with active Hepatitis B or C or human immunodeficiency virus (HIV) infection with non-controlled disease according to the treating physician.
- •Patients with any other medical conditions (such as psychiatric illness, infectious diseases, abnormal physical examination or laboratory findings) that in the opinion of the investigator may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment-related complications.
研究组 & 干预措施
Endometrial cancer
Experimental
ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with advanced endometrial cancer, up to 12 months from initiation.
干预措施: ABTL0812 in combination with paclitaxel and carboplatin (Drug)
Squamous non-small cell lung cancer
Experimental
ABTL0812 (starting 1,300 mg tid orally) in combination with paclitaxel and carboplatin will be given to patients with squamous NSCLC, up to 12 months from initiation.
干预措施: ABTL0812 in combination with paclitaxel and carboplatin (Drug)
结局指标
主要结局
Emergent Adverse Events
时间窗: 1 year
Related Adverse Events as Assessed by CTCAE v4.03
次要结局
- Progression Free Survival (PFS)(2 years)
- Time to Progression (TP)(2 years)
- Objective response rate (ORR)(2 years)
- Duration of Response (DR)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
暂停
1 期
A Study of ABTL0812 in Pancreatic CancerPancreatic CancerNCT03417921Ability Pharmaceuticals SL60
Unknown
1 期
A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder CancerMuscle Invasive Bladder CancerNCT04813107Jiangsu Yahong Meditech Co., Ltd aka Asieris79
招募中
2 期
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical CancerCervical CancerNCT06123884Bio-Thera Solutions526
已完成
2 期
A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant RecipientsChronic Hepatitis C InfectionNCT01782495AbbVie129
已完成
1 期
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer PatientsNon-hematologic MalignanciesMetastatic MelanomaPrimary Peritoneal CancerFallopian Tube CancerOvarian CancerHepatocellular CarcinomaBreast CancerNCT00526617AbbVie41